title: Therapeutic Silencing of Bcl-2 by Systemically Administered siRNA Nanotherapeutics Inhibits Tumor Growth by Autophagy and Apoptosis and Enhances the Efficacy of Chemotherapy in Orthotopic Xenograft Models of ER (-) and ER (+) Breast Cancer.
abstract: Bcl-2 is overexpressed in about a half of human cancers and 50-70% of breast cancer patients, thereby conferring resistance to conventional therapies and making it an excellent therapeutic target. Small interfering RNA (siRNA) offers novel and powerful tools for specific gene silencing and molecularly targeted therapy. Here, we show that therapeutic silencing of Bcl-2 by systemically administered nanoliposomal (NL)-Bcl-2 siRNA (0.15 mg siRNA/kg, intravenous) twice a week leads to significant antitumor activity and suppression of growth in both estrogen receptor-negative (ER(-)) MDA-MB-231 and ER-positive (+) MCF7 breast tumors in orthotopic xenograft models (P < 0.05). A single intravenous injection of NL-Bcl-2-siRNA provided robust and persistent silencing of the target gene expression in xenograft tumors. NL-Bcl-2-siRNA treatment significantly increased the efficacy of chemotherapy when combined with doxorubicin in both MDA-MB-231 and MCF-7 animal models (P < 0.05). NL-Bcl-2-siRNA treatment-induced apoptosis and autophagic cell death, and inhibited cyclin D1, HIF1α and Src/Fak signaling in tumors. In conclusion, our data provide the first evidence that in vivo therapeutic targeting Bcl-2 by systemically administered nanoliposomal-siRNA significantly inhibits growth of both ER(-) and ER(+) breast tumors and enhances the efficacy of chemotherapy, suggesting that therapeutic silencing of Bcl-2 by siRNA is a viable approach in breast cancers.Molecular Therapy-Nucleic Acids (2013) 2, e121; doi:10.1038/mtna.2013.45; published online 10 September 2013.
authors.affiliation: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030, USA.
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Tekedereli
authors.forename: S Neslihan
authors.initials: SN
authors.lastname: Alpay
authors.forename: Ugur
authors.initials: U
authors.lastname: Akar
authors.forename: Erkan
authors.initials: E
authors.lastname: Yuca
authors.forename: Cristian
authors.initials: C
authors.lastname: Ayugo-Rodriguez
authors.forename: He-Dong
authors.initials: HD
authors.lastname: Han
authors.forename: Anil K
authors.initials: AK
authors.lastname: Sood
authors.forename: Gabriel
authors.initials: G
authors.lastname: Lopez-Berestein
authors.forename: Bulent
authors.initials: B
authors.lastname: Ozpolat
references.citation: Autophagy. 2007 Mar-Apr;3(2):142-4
references.pmid: 17204849
references.citation: Nature. 2001 May 24;411(6836):494-8
references.pmid: 11373684
references.citation: Cancer Res. 2008 Nov 1;68(21):8843-51
references.pmid: 18974128
references.citation: Apoptosis. 2008 Apr;13(4):531-42
references.pmid: 18322799
references.citation: Nature. 2004 Sep 16;431(7006):371-8
references.pmid: 15372045
references.citation: Cancer Res. 2010 Jul 15;70(14):5942-52
references.pmid: 20634405
references.citation: Autophagy. 2011 May;7(5):457-65
references.pmid: 21150268
references.citation: Curr Opin Oncol. 2009 Nov;21(6):516-23
references.pmid: 19730103
references.citation: Int J Cancer. 2000 Apr 15;86(2):188-96
references.pmid: 10738245
references.citation: FASEB J. 2002 Sep;16(11):1453-5
references.pmid: 12205045
references.citation: Mol Cancer Ther. 2010 May;9(5):1180-7
references.pmid: 20423989
references.citation: Nat Cell Biol. 2004 Dec;6(12):1221-8
references.pmid: 15558033
references.citation: Nat Rev Cancer. 2011 Jan;11(1):59-67
references.pmid: 21160526
references.citation: Oncogene. 1997 Jun 19;14(24):2971-7
references.pmid: 9205104
references.citation: Oncogene. 2002 Dec 12;21(57):8843-51
references.pmid: 12483536
references.citation: FEBS Lett. 1998 Dec 4;440(3):419-24
references.pmid: 9872414
references.citation: Nat Rev Cancer. 2005 Sep;5(9):726-34
references.pmid: 16148885
references.citation: Mol Cancer Ther. 2007 Jan;6(1):101-11
references.pmid: 17237270
references.citation: Science. 2000 Dec 1;290(5497):1717-21
references.pmid: 11099404
references.citation: Biochem Biophys Res Commun. 2002 Aug 30;296(4):1000-4
references.pmid: 12200148
references.citation: Hum Pathol. 2012 Jan;43(1):23-30
references.pmid: 21777944
references.citation: Neurochem Res. 2009 Jan;34(1):66-78
references.pmid: 18357521
references.citation: Nat Rev Drug Discov. 2004 Apr;3(4):318-29
references.pmid: 15060527
references.citation: Autophagy. 2010 Apr;6(3):322-9
references.pmid: 20224296
references.citation: Int J Oncol. 2009 Feb;34(2):313-9
references.pmid: 19148464
references.citation: Nat Rev Mol Cell Biol. 2008 Jan;9(1):47-59
references.pmid: 18097445
references.citation: Hematol Oncol Clin North Am. 1995 Apr;9(2):451-73
references.pmid: 7642473
references.citation: Mol Cancer Res. 2007 Jan;5(1):95-108
references.pmid: 17259349
references.citation: Cancer J. 2003 Jan-Feb;9(1):33-41
references.pmid: 12602766
references.citation: Exp Ther Med. 2010 Sep;1(5):747-754
references.pmid: 22993598
references.citation: Cell. 2005 Sep 23;122(6):927-39
references.pmid: 16179260
references.citation: Int J Cancer. 2002 Oct 1;101(4):317-26
references.pmid: 12209955
references.citation: Nat Rev Drug Discov. 2010 Aug;9(8):615-27
references.pmid: 20616808
references.citation: J Intern Med. 2010 Jan;267(1):44-53
references.pmid: 20059643
references.citation: Autophagy. 2008 Jul;4(5):669-79
references.pmid: 18424910
references.citation: Nat Rev Drug Discov. 2007 Apr;6(4):304-12
references.pmid: 17396135
references.citation: Int J Oncol. 2003 Apr;22(4):875-81
references.pmid: 12632082
references.citation: Semin Oncol. 2003 Oct;30(5 Suppl 16):143-9
references.pmid: 14613035
references.citation: Cancer Res. 1999 Apr 1;59(7 Suppl):1693s-1700s
references.pmid: 10197582
references.citation: Autophagy. 2007 Sep-Oct;3(5):480-3
references.pmid: 17507797
references.citation: J Cell Biochem. 2005 Aug 15;95(6):1214-23
references.pmid: 15962308
references.citation: PLoS One. 2010 Jul 27;5(7):e11772
references.pmid: 20668552
references.citation: Cell Death Differ. 2011 Mar;18(3):452-64
references.pmid: 20885445
references.citation: Oncogene. 2008 Oct 27;27(50):6398-406
references.pmid: 18955968
references.citation: Mol Pharmacol. 2006 Oct;70(4):1330-9
references.pmid: 16825486
references.citation: J Control Release. 2006 Aug 10;114(1):100-9
references.pmid: 16831482